Stock Performance: AKESO (09926.HK) opened 4.7% higher at HKD177 with a pre-market trading volume of 2.2197 million shares, amounting to HKD381 million.
Revenue Growth: The company's revenue for the first half of 2025 increased by 37.7% year-on-year to RMB1.412 billion, while gross profit rose by 18.8% to RMB1.121 billion.
Increased Losses: AKESO reported a deeper interim loss of RMB570 million, up from RMB239 million in the previous year, primarily due to higher investment loss provisions and R&D expenses.
No Dividend Declared: The company did not declare any dividends, and its loss per share (LPS) was recorded at RMB64 cents.
09926
$117.1+Infinity%1D
Analyst Views on 09926
Wall Street analysts forecast 09926 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 09926 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Analyst Rating
Wall Street analysts forecast 09926 stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for 09926 is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
0 Hold
0 Sell
Current: 116.900
Low
Averages
High
Current: 116.900
Low
Averages
High
CICC
CICC
Outperform
to
NULL
downgrade
2025-10-22
Reason
CICC
CICC
Price Target
2025-10-22
downgrade
Outperform
to
NULL
Reason
The analyst rating for AKESO (09926.HK) is maintained as "Outperform" by CICC due to the impressive interim analysis data presented from the HARMONi-6 study and the revision of the HARMONi-3 trial protocol. CICC believes that the separate analysis of histological types will enable AKESO to obtain clinical data earlier and that increasing the enrolled population will enhance overall survival (OS) performance. However, the target price was cut by 18.2% to HKD184, reflecting a downward adjustment in the valuation center for innovative drugs in the Hong Kong stock market.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
